Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1604 plus paclitaxel-platinum in recurrent or metastatic cervical cancer
CTR20211777Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Started May 2022; status: completed.
02
Drugs
iparomlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20211777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211777.